In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Single investor buys 16mm common shares of Cell Therapeutics

Executive Summary

On the heels of a $20mm preferred stock placement completed in April, cancer company Cell Therapeutics netted $19mm through the sale this month of 16mm common shares at $1.25 each (an 89% premium) to Iroquois Master Fund. The sole investor also received five-year warrants to purchase up to 4.8mm more shares at an exercise price of $1.40. Rodman & Renshaw was the placement agent.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies